ABV100 platform will become a replacement for rapid acting insulin that can be used anywhere and with any patient type (T1D, T2D, Injections, pumps)
Protects against hypoglycemia allowing safer use of insulin and better control of diabetes that in turn allows much improved long term health
Pharmacological platform leverages two well known FDA-approved peptides (many decades of use in humans)
Human proof of concept already achieved with prototype co-formulations
DOWNLOAD CORPORATE PRESENTATION
Please contact me about Abvance Therapeutics news.
Abvance Therapeutics does not sell, rent or provide your email to any third party.